Objective: To elucidate factors that influence Philippine women to deliver at home and not be attended by a healthcare professional.
Methods: Analysis of hospital data that were collected through Global Positioning System technology uploaded into the WHO HealthMapper and data on 7380 women from the Philippines Demographic and Health Survey, 2003.
Results: Most of the home deliveries that were not attended by healthcare professionals occurred within 15 km of a hospital. Women who had home deliveries and were not attended by a healthcare professional were more likely to be of low educational and economic status and to reside in rural houses without basic amenities (P<0.001). Obtaining money (83.0%), transport (48.1%), and a companion (35.0%) were identified as barriers to getting treatment. Death rates of neonates born to these women were not statistically different from those of neonates who were born in a healthcare facility (OR 1.0; 95% CI, 0.63-1.57; P<0.99).
Conclusion: Most deliveries that were not attended by a healthcare professional occurred near a hospital. Financial barriers will need to be addressed to increase the number of deliveries in a healthcare facility. The apparent failure of hospitals to reduce newborn mortality may be related to suboptimal newborn care practices.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijgo.2010.06.020 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Review of Falls And Injuries Of Nursing Home Residents Presenting To The Emergency Department.
QJM
January 2025
Tallaght hospital, Dept. of Age Related Healthcare; Trinity College Dublin, Dept. of Medical Gerontology.
Background: Falls are frequently reported within the HSE. The Irish Longitudinal Study on Ageing(TILDA) found that 40% of over 50 s experience a fall in a two year period, with 20% requiring hospital attendance (1). It has been estimated that the cost of injuries related to falls in older people will increase exponentially over the coming years (2).
View Article and Find Full Text PDFRed cell distribution width as a cardiovascular risk predictor in adults with hypertension in sub-Saharan Africa.
J Hum Hypertens
January 2025
Department of Pediatrics and Child Health, University of Ilorin, Ilorin, Nigeria.
Article Synopsis
- Red cell distribution width (RDW) is a measure of variability in red blood cell sizes and may indicate cardiovascular disease (CVD) risk, especially in low-resource areas, according to a study in Ghana and Nigeria.
- The study involved 319 adults with hypertension who underwent assessments like blood pressure and RDW measurement, revealing an average RDW of 13.96% and a median CVD risk score of 8.11%.
- Findings showed that RDW is positively correlated with age, systolic and diastolic blood pressure, and WHO CVD risk scores, suggesting RDW could be a useful predictor of CVD risk in this population, particularly with an RDW cutoff of >14
C5 complement inhibition versus FcRn modulation in generalised myasthenia gravis.
J Neurol Neurosurg Psychiatry
January 2025
Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
Background: Myasthenia gravis (MG) is an autoimmune disorder affecting neuromuscular junctions, leading to fluctuating muscle weakness. While many patients respond well to standard immunosuppression, a substantial subgroup faces ongoing disease activity. Emerging treatments such as complement factor C5 inhibition (C5IT) and neonatal Fc receptor (FcRn) antagonism hold promise for these patients.
View Article and Find Full Text PDFDurvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.
Lancet
January 2025
Department of Diagnostic and Interventional Radiology, University of Pisa School of Medicine, Pisa, Italy.
Background: Transarterial chemoembolisation (TACE) is standard of care for patients with unresectable hepatocellular carcinoma that is amenable to embolisation; however, median progression-free survival is still approximately 7 months. We aimed to assess whether adding durvalumab, with or without bevacizumab, might improve progression-free survival.
Methods: In this multiregional, randomised, double-blind, placebo-controlled, phase 3 study (EMERALD-1), adults aged 18 years or older with unresectable hepatocellular carcinoma amenable to embolisation, an Eastern Cooperative Oncology Group performance status of 0 or 1 at enrolment, and at least one measurable intrahepatic lesion per modified Response Evaluation Criteria in Solid Tumours (RECIST) were enrolled at 157 medical sites including research centres and general and specialist hospitals in 18 countries.
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study.
Lancet
January 2025
Mount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Liver Cancer Translational Research Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Spain; Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain. Electronic address:
Article Synopsis
- TACE is the standard treatment for patients with unresectable, non-metastatic hepatocellular carcinoma, and this study evaluates the effectiveness of adding lenvatinib and pembrolizumab to TACE compared to a placebo.
- The multicenter, randomised, double-blind phase 3 study (LEAP-012) involved participants from 137 sites across 33 countries who were randomly assigned to receive either TACE with the new drugs or TACE with a placebo.
- The primary endpoints were progression-free survival and overall survival, and the results reported are from the first interim analysis, which serves as the final analysis for progression-free survival.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!